secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001140361-22-038593
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q3 revenue $67.7M (+45% YoY); net loss $1.09/share; secures $775M financing
--------------------------------------------------------------------------------

- ARIKAYCE total revenue of $67.7M: $49.5M U.S., $14.5M Japan, $3.7M Europe/RoW.
- Net loss of $131.1M ($1.09 per share) vs $112.7M ($0.96) in Q3 2021.
- Cash and marketable securities $513.3M; strategic financings added $775M gross proceeds.
- Full-year 2022 ARIKAYCE revenue expected to grow at least 30% YoY.
- Phase 3 ASPEN (brensocatib) enrollment on track; topline data expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/0001140361-22-038593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/brhc10043308_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-038593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer